December 8, 2020
SeraNovo names Michiel Van Speybroeck as head of development for clinical studies
SeraNovoa pharmaceutical company with a breakthrough proprietary formulation platform for enhancing drug bioavailability has appointed Dr Michiel Van Speybroeck to the role of Chief Development Officer (CDO) with immediate effect.